RESUMO
BACKGROUND: The role of apoptosis, and more specifically the Fas pathway, is still unclear in squamous cell laryngeal cancer. MATERIALS AND METHODS: By means of immunohistochemistry, the expression of three genes involved in different pathways of apoptosis (p53, Bcl-2 and Fas) was studied in a series of 45 squamous cell laryngeal cancers from Spanish patients. RESULTS: Of the studied tumors, 25 (55.6%) expressed mutant p53, 22 (48.9%) expressed Bcl-2 and 25 (55.6%) expressed Fas. p53, Bcl-2 and Fas expression were not correlated with each other. The only tested factors associated with significantly better survival of the patients were low tumor stage (p = 0.0074), the absence of metastatic regional nodes (p = 0.0009) and Fas expression (p = 0.029). Fas expression was not correlated with the expression of any other tested parameter. CONCLUSION: The determination of Fas expression in squamous cell laryngeal carcinoma by means of immunohistochemistry using the GM30/CD95 antibody could be of potential use in the clinic.
Assuntos
Carcinoma de Células Escamosas/metabolismo , Neoplasias Laríngeas/metabolismo , Receptor fas/biossíntese , Adulto , Idoso , Idoso de 80 Anos ou mais , Apoptose/fisiologia , Carcinoma de Células Escamosas/patologia , Humanos , Imuno-Histoquímica , Neoplasias Laríngeas/patologia , Metástase Linfática , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Taxa de Sobrevida , Proteína Supressora de Tumor p53/biossínteseRESUMO
Ductal carcinoma in situ (DCIS) represents between 0% and 7% of breast cancers diagnosed in men. Noninvasive intracystic papillary carcinoma is a form of DCIS and is therefore an extremely rare presentation of breast cancer. The imaging technique that provides the greatest information on these lesions is ultrasonography. Treatment of DCIS in men continues to be controversial. We present a case of noninvasive intracystic papillary carcinoma treated with partial mastectomy followed by radiotherapy and tamoxifen therapy. After 1 year of follow-up, the patient shows no signs of recurrence.